BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program

Core Viewpoint - BrainStorm Cell Therapeutics Inc. is set to hold a mid-year corporate update on July 8, 2024, to discuss positive developments in the NurOwn® program for neurodegenerative diseases [1] Company Overview - BrainStorm Cell Therapeutics is a leading developer of autologous adult stem cell therapeutics targeting neurodegenerative diseases [3] - The company holds exclusive rights to the NurOwn® technology platform, which produces autologous MSC-NTF cells, and has received Orphan Drug designation from the FDA and EMA for ALS treatment [3] - BrainStorm has completed a Phase 3 trial for ALS (NCT03280056) and a Phase 2 trial for progressive MS (NCT03799718), both supported by grants from various organizations [3] Conference Call Details - The conference call will feature presentations from the President and CEO, Chaim Lebovits, and the newly appointed COO, Hartoun Hartounian, along with a Q&A session [1] - Participants can submit questions in advance until July 5, 2024 [1] - The call can be accessed via toll-free and international numbers, with a replay available until July 22, 2024 [2]